ERBB2 and inflammatory breast carcinoma: In a phase 2 single arm trial 49 patients with IBC were stratified according HER2 and EGFR expression in two different groups: cohort A (HER2+ plus or minus EGFR+ IBC) or cohort B (HER2- and EGFR+) [56].